145 related articles for article (PubMed ID: 35967311)
1. Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages.
Schoenbrunn A; Juelke K; Reipert BM; Horling F; Turecek PL
Front Immunol; 2022; 13():894411. PubMed ID: 35967311
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Horling FM; Reipert BM; Allacher P; Engl W; Pan L; Tangada S
Blood Adv; 2024 Jun; 8(11):2726-2739. PubMed ID: 38564770
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
F1000Res; 2021; 10():1049. PubMed ID: 35136579
[No Abstract] [Full Text] [Related]
4. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
5. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
[TBL] [Abstract][Full Text] [Related]
6. Damoctocog Alfa Pegol: A Review in Haemophilia A.
Paik J; Deeks ED
Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.
Wu Y; Sun SX; Fan T
J Blood Med; 2022; 13():517-524. PubMed ID: 36188439
[TBL] [Abstract][Full Text] [Related]
9. Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety.
Stidl R; Denne M; Goldstine J; Kadish B; Korakas KI; Turecek PL
Pharmaceuticals (Basel); 2018 Jul; 11(3):. PubMed ID: 30049994
[TBL] [Abstract][Full Text] [Related]
10. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM; Tellier P; Douville J; Mansell P; Graziano MJ; Mangipudy RS; Brodie TA; Achanzar WE
Toxicol Lett; 2019 Dec; 317():120-129. PubMed ID: 31580884
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
Lissitchkov T; Willemze A; Jan C; Zilberstein M; Katragadda S
Res Pract Thromb Haemost; 2023 May; 7(4):100176. PubMed ID: 37538505
[TBL] [Abstract][Full Text] [Related]
12. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins.
Rudmann DG; Alston JT; Hanson JC; Heidel S
Toxicol Pathol; 2013; 41(7):970-83. PubMed ID: 23788571
[TBL] [Abstract][Full Text] [Related]
13. Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
You CW; Baek HJ; Park SK; Park YS; Shin HJ; Engl W; Tangada S
Blood Res; 2019 Sep; 54(3):198-203. PubMed ID: 31730687
[TBL] [Abstract][Full Text] [Related]
14. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct
Bjørnsdottir I; Støvring B; Søeborg T; Jacobsen H; Sternebring O
Drugs R D; 2020 Jun; 20(2):75-82. PubMed ID: 32152818
[TBL] [Abstract][Full Text] [Related]
15. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.
Stidl R; Fuchs S; Bossard M; Siekmann J; Turecek PL; Putz M
Haemophilia; 2016 Jan; 22(1):54-64. PubMed ID: 26219204
[TBL] [Abstract][Full Text] [Related]
16. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.
Bendele A; Seely J; Richey C; Sennello G; Shopp G
Toxicol Sci; 1998 Apr; 42(2):152-7. PubMed ID: 9579027
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction.
Baumann A; Piel I; Hucke F; Sandmann S; Hetzel T; Schwarz T
Eur J Pharm Sci; 2019 Mar; 130():11-20. PubMed ID: 30654111
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG.
Ivens IA; Banczyk D; Gutberlet K; Jackman S; Vauléon S; Frisk AL
Toxicol Pathol; 2019 Jul; 47(5):585-597. PubMed ID: 31132933
[TBL] [Abstract][Full Text] [Related]
19. Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.
Byrd RA; Blackbourne JL; Knadler MP; Schultze AE; Vahle JL
Toxicol Pathol; 2017 Apr; 45(3):402-415. PubMed ID: 28421968
[TBL] [Abstract][Full Text] [Related]
20. Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP).
Sternebring O; Gabel-Jensen C; Jacobsen H; Benie AJ; Bjørnsdottir I
BioDrugs; 2019 Dec; 33(6):673-681. PubMed ID: 31549312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
